PBT: Up almost 20% on the NASDAQ to USD$2.96 (AUD$0.285) on turnover of 6.7m which is five times the average.
I think people are finally starting to take PBT2 seriously as a potential drug candidate against Alzheimer's disease. The new test announced by CGS which uses elevated amyloid protein levels in the brain as a marker to detect the disease early, even before symptoms are obvious, is most likely having a positive impact as well. PBT2 works by preventing the accumulation of the beta amyloid protein in the brain. This stock will be a life changer if they succeed.
